This 2023 statement updates clinical guidance for homozygous familial
hypercholesterolaemia (HoFH), explains the genetic complexity, and provides pragmatic …

Disturbed cholesterol homeostasis plays critical roles in the development of multiple
diseases, such as cardiovascular diseases (CVD), neurodegenerative diseases and …

This contemporary, international, evidence-informed guidance aims to achieve the greatest
good for the greatest number of people with familial hypercholesterolaemia (FH) across …

Dyslipidemias have emerged as prevalent disorders among patients, posing significant risks
for the development and progression of cardiovascular diseases. These conditions are …

Familial hypercholesterolaemia (FH) is a common autosomal semi-dominant and highly
penetrant disorder of the low-density lipoprotein (LDL) receptor pathway, characterised by …

Cardiovascular diseases (CVD) are the leading cause of death worldwide. Since the
establishment of the “lipid hypothesis”, according to which, cholesterol level is directly …

Abstract Aims Homozygous familial hypercholesterolaemia (HoFH) is a rare disorder
characterized by markedly elevated circulating low-density lipoprotein cholesterol (LDL-C) …

Hypercholesterolemia is notoriously difficult to control in most patients with HoFH, but multi-
LLT, including newer drugs, allows reduction of LDL-C to levels unimaginable until a few …

Familial hypercholesterolemia (FH) is a hereditary disorder that causes severely elevated
low-density lipoprotein (LDL-C) levels, which leads to an increased risk for premature …

Several observations have shown that elevated levels of low-density lipoprotein cholesterol
(LDL-C) are a cause of cardiovascular disease. Lowering LDL-C is a key strategy for …